

Lipocine Inc.
Form 3
August 02, 2013

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

| | | | | |
|--|--|---|---|--|
| 1. Name and Address of Reporting Person * | | 2. Date of Event Requiring Statement | 3. Issuer Name and Ticker or Trading Symbol | |
| Â ELAN CORP PLC | | (Month/Day/Year) | Lipocine Inc. [MBARD] | |
| (Last) | (First) | (Middle) | 07/24/2013 | |
| TREASURY BUILDING,Â LOWER GRAND CANAL STREET | | | 4. Relationship of Reporting Person(s) to Issuer | 5. If Amendment, Date Original Filed(Month/Day/Year) |
| (Street) | (Check all applicable) | | | |
| | <input type="checkbox"/> Director | <input checked="" type="checkbox"/> 10% Owner | | |
| | <input type="checkbox"/> Officer | <input type="checkbox"/> Other | 6. Individual or Joint/Group Filing(Check Applicable Line) | |
| | (give title below) (specify below) | | <input type="checkbox"/> Form filed by One Reporting Person | |
| DUBLIN 2,Â L2Â 00000 | <input checked="" type="checkbox"/> Form filed by More than One Reporting Person | | | |
| (City) | (State) | (Zip) | | |

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|---|--|---|
| Common Stock | 800,394 | I ⁽¹⁾ | Indirect ⁽¹⁾ |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative | 5. Ownership Form of Derivative Security: | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|--|---|---|---|---|
|--|--|---|---|---|---|

Edgar Filing: Lipocine Inc. - Form 3

| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | Security | Direct (D) or Indirect (I) (Instr. 5) |
|------------------|-----------------|-------|----------------------------|----------|---------------------------------------|
|------------------|-----------------|-------|----------------------------|----------|---------------------------------------|

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| ELAN CORP PLC TREASURY BUILDING LOWER GRAND CANAL STREET DUBLIN 2, L2 00000 | ^ | ^ X | ^ | ^ |
| Elan Pharma International LTD TREASURY BUILDING LOWER GRAND CANAL STREET DUBLIN 2, L2 00000 | ^ | ^ X | ^ | (1) |
| ELAN INTERNATIONAL SERVICES LTD C/O TREASURY BUILDING LOWER GRAND CANAL STREET DUBLIN 2, L2 00000 | ^ | ^ X | ^ | ^ |

Signatures

/s/ William F. Daniel, Executive Vice President and Company Secretary

08/02/2013

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) 718,483 shares are directly owned by Elan International Services Limited, an indirect wholly-owned subsidiary of Elan Corporation, plc ("Elan"), and 81,911 shares are directly owned by Elan Pharma International Limited, an indirect wholly-owned subsidiary of Elan. Elan Pharma International Limited may be deemed to be a member of a 13(d) group (with Elan and Elan International Services Limited) constituting a 10% owner.

^

Remarks:

Exhibit List: ^ ^ Exhibit 99.1 ^ - ^ Joint Filer ^ Information

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.